Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 6392Neoplasms 408Ovarian Neoplasms 308Triple Negative Breast Neoplasms 286Prostatic Neoplasms 280Lung Neoplasms 271Colorectal Neoplasms 255Neoplasm Metastasis 254Carcinoma, Non-Small-Cell Lung 221Breast Neoplasms, Male 201Colonic Neoplasms 168Motor Activity 166Pancreatic Neoplasms 164Melanoma 157Carcinoma, Intraductal, Noninfiltrating 139Stomach Neoplasms 128Uterine Cervical Neoplasms 127Head and Neck Neoplasms 124Fatigue 104Breast Carcinoma In Situ 103Carcinoma, Ovarian Epithelial 98Endometrial Neoplasms 96Lymphedema 95Carcinoma, Renal Cell 94Urinary Bladder Neoplasms 93Pain 90Sarcoma 89Small Cell Lung Carcinoma 85Lymphoma 83Esophageal Neoplasms 81

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Metastatic Breast Cancer × Breast × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡